Skip to main content
ACTRIS will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 to check if you are unsure if something is a scam or visit ScamShield (opens in new tab) for more information.

Advanced Cell Therapy and Research Institute, Singapore (ACTRIS)

ACTRIS signs MOU with Cell Therapies

Topics

Partnerships

11 February 2026

ACTRIS has signed an MoU with Cell Therapies Pty Ltd to expand access to advanced cell and gene therapies across Singapore and the Asia Pacific region.

Eight professionals posing in front of a Cell Therapies sign on a wall inside an office building.

We are pleased to announce that we have signed a Memorandum of Understanding (MoU) with Cell Therapies Pty Ltd (opens in new tab), Australia’s Contract Development and Manufacturing Organisation (CDMO) for cell and gene therapies (CGT).

This MoU marks the first step in a strategic collaboration aimed at accelerating ACTRIS’ operational readiness to meet the increasing clinical demand of using cellular therapeutics to treat various life-threatening diseases. By combining our state-of-the-art GMP infrastructure and vision to be a regional Centre of Excellence with Cell Therapies’ decades of experience in CGT development, clinical translation, and commercial manufacturing, we aim to expand patient access to advanced therapies across Singapore and the Asia Pacific region.

Together, we will optimise GMP-compliant manufacturing processes, enable efficient technology transfer and scale-up, strengthen regulatory strategies, and build long-term workforce and infrastructure capabilities. This collaboration also reflects Cell Therapies’ commitment to its Asia Pacific Alliance Model (APAM), supporting a coordinated pathway for global sponsors advancing CGT programmes across the region.

We look forward to deepening this collaboration as we jointly contribute to a robust, sustainable, and innovation-driven CGT ecosystem in Asia-Pacific.